Literature DB >> 7909242

Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype.

U Dianzani1, P Omedè, F Marmont, D DiFranco, A Fusaro, M Bragardo, V Redoglia, F Giaretta, L Mairone, M Boccadoro.   

Abstract

Peripheral blood (PB) T cells from 56 patients with B-cell chronic lymphocytic leukemia (B-CLL) were analyzed by two- and three-color immunofluorescence (IF) to determine the expansion of distinct T-cell subsets and their relationship with the clinical and biological features of the disease. We detected the expansion of an unusual T-cell subpopulation expressing lower CD4 or CD8 levels (CD4lo, CD8lo) than classic T cells (CD4hi, CD8hi). This subpopulation also expressed low levels of the CD3/TCR alpha/beta complex and was CD19-CD13-CD14-. A phenotypic analysis probing the activation level of CD4lo, CD8lo, CD4hi, and CD8hi cells showed that they comprised increased counts of HLA-DR+, CD11b+, CD45R0+, and CD45RA+ cells. Subset expansion ranged from 2.1- to 13.6-fold. Statistical analysis showed that the size of some of these subsets was correlated to intrinsic features of the tumor. First, CD4loHLA-DR+ cell counts were higher in patients with stage A than those with stages B and C disease. Second, CD8loHLA-DR+ cell counts were higher in patients in stable remission than in those at diagnosis. Third, CD4loHLA-DR+, CD4loCD45R0+, CD4loCD45RA+, and CD4hiCD11b+ cell counts were higher in patients whose tumor cells expressed high levels of surface immunoglobulin (sIg) than in those expressing low levels. The involvement of CD4lo and CD8lo cells in most of these correlations suggests that they may be tumor-reactive cells. Similar cells described in human and murine autoimmune disease have been shown to be autoreactive anergic cells, which may derive from nonclassic pathways of T-cell development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909242

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Growth and survival of B-chronic lymphocytic leukaemia cells.

Authors:  O Söderberg
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

2.  Elimination of CD4lowHLA-G+ T cells overcomes castration-resistance in prostate cancer therapy.

Authors:  Chao Wang; Jiahuan Chen; Qianfei Zhang; Wang Li; Shengbo Zhang; Yanjie Xu; Fang Wang; Bing Zhang; Yan Zhang; Wei-Qiang Gao
Journal:  Cell Res       Date:  2018-10-08       Impact factor: 25.617

3.  Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia.

Authors:  Angélique Biancotto; Pradeep K Dagur; John C Fuchs; Adrian Wiestner; C Bruce Bagwell; J Philip McCoy
Journal:  Mod Pathol       Date:  2011-11-18       Impact factor: 7.842

4.  Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia.

Authors:  S J Hill; S H Peters; M J Ayliffe; J Merceica; A S Bansal
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

5.  Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells.

Authors:  Simon H Apte; Adriana Baz; Penny Groves; Anne Kelso; Norbert Kienzle
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-06       Impact factor: 11.205

Review 6.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

7.  Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia.

Authors:  I Frydecka; A Kosmaczewska; D Bocko; L Ciszak; D Wolowiec; K Kuliczkowski; I Kochanowska
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

8.  CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).

Authors:  Adam Trickey; Margaret T May; Philipp Schommers; Jan Tate; Suzanne M Ingle; Jodie L Guest; M John Gill; Robert Zangerle; Mike Saag; Peter Reiss; Antonella d'Arminio Monforte; Margaret Johnson; Viviane D Lima; Tim R Sterling; Matthias Cavassini; Linda Wittkop; Dominique Costagliola; Jonathan A C Sterne
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.